Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors inside the central nervous method, conolidine modulates alternate molecular targets. A Science Advances review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://ferdinandh195fwo4.wikicorrespondence.com/user